Trial Profile
A Study Assessing the Spatial and Kinetic Features of [18F]MK-6240 Binding in Target and Off-Target Regions to Determine the Optimal Imaging Parameters in Humans Ranging from Young Controls to Patients with Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Oct 2018
Price :
$35
*
At a glance
- Drugs Florquinitau F18 (Primary) ; Pittsburgh compound B
- Indications Alzheimer's disease; Cognition disorders
- Focus Diagnostic use
- 04 Oct 2018 New trial record